Bio-Techne Corp (NASDAQ: TECH) has a higher price-to-earnings ratio of 80.92x compared to its average ratio, The 36-month beta value for TECH is at 1.27. Analysts have varying views on the stock, with 2 analysts rating it as a “buy,” 4 rating it as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for TECH is 157.22M, and currently, shorts hold a 2.02% of that float. The average trading volume for TECH on November 14, 2024 was 846.14K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
TECH) stock’s latest price update
The stock of Bio-Techne Corp (NASDAQ: TECH) has increased by 2.04 when compared to last closing price of 74.41.Despite this, the company has seen a gain of 0.13% in its stock price over the last five trading days. prnewswire.com reported 2024-11-11 that R&D Systems Hematology Controls and Calibrators has completed the Class B Certification under the new European Union In Vitro Diagnostic Regulation This press release updates the IVDR Classification to Class B from the prior Class C. MINNEAPOLIS, Nov. 11, 2024 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) has recently achieved In Vitro Diagnostic Regulation (IVDR) certification for its R&D Systems Hematology Controls and Calibrators.
TECH’s Market Performance
TECH’s stock has risen by 0.13% in the past week, with a monthly rise of 3.18% and a quarterly rise of 1.36%. The volatility ratio for the week is 2.48% while the volatility levels for the last 30 days are 3.15% for Bio-Techne Corp The simple moving average for the last 20 days is 3.94% for TECH’s stock, with a simple moving average of 3.16% for the last 200 days.
Analysts’ Opinion of TECH
Many brokerage firms have already submitted their reports for TECH stocks, with Citigroup repeating the rating for TECH by listing it as a “Neutral.” The predicted price for TECH in the upcoming period, according to Citigroup is $85 based on the research report published on May 22, 2024 of the current year 2024.
Scotiabank, on the other hand, stated in their research note that they expect to see TECH reach a price target of $80. The rating they have provided for TECH stocks is “Sector Outperform” according to the report published on February 08th, 2024.
Stifel gave a rating of “Hold” to TECH, setting the target price at $65 in the report published on February 02nd of the current year.
TECH Trading at 2.19% from the 50-Day Moving Average
After a stumble in the market that brought TECH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -11.27% of loss for the given period.
Volatility was left at 3.15%, however, over the last 30 days, the volatility rate increased by 2.48%, as shares surge +5.75% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +6.76% upper at present.
During the last 5 trading sessions, TECH rose by +0.13%, which changed the moving average for the period of 200-days by +4.43% in comparison to the 20-day moving average, which settled at $73.05. In addition, Bio-Techne Corp saw -1.59% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TECH starting from BAUMGARTNER ROBERT V, who sale 16,000 shares at the price of $72.10 back on Aug 08 ’24. After this action, BAUMGARTNER ROBERT V now owns 43,401 shares of Bio-Techne Corp, valued at $1,153,664 using the latest closing price.
ROBERT V. BAUMGARTNER, the Director of Bio-Techne Corp, proposed sale 16,000 shares at $72.10 during a trade that took place back on Aug 08 ’24, which means that ROBERT V. BAUMGARTNER is holding shares at $1,153,664 based on the most recent closing price.
Stock Fundamentals for TECH
Current profitability levels for the company are sitting at:
- 0.2 for the present operating margin
- 0.67 for the gross margin
The net margin for Bio-Techne Corp stands at 0.13. The total capital return value is set at 0.09. Equity return is now at value 7.29, with 5.49 for asset returns.
Based on Bio-Techne Corp (TECH), the company’s capital structure generated 0.13 points at debt to capital in total, while cash flow to debt ratio is standing at 0.97. The debt to equity ratio resting at 0.15. The interest coverage ratio of the stock is 17.59.
Currently, EBITDA for the company is 326.66 million with net debt to EBITDA at 0.61. When we switch over and look at the enterprise to sales, we see a ratio of 10.48. The receivables turnover for the company is 5.24for trailing twelve months and the total asset turnover is 0.43. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.56.
Conclusion
In conclusion, Bio-Techne Corp (TECH) has had a better performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
